Jay Luly, Enanta CEO
Enanta culls internal NASH work, betting on an out-licensing strategy in the disaster-strewn field
Cracking NASH has been the holy grail for years in liver drug development, but the field has so far proven a wasteland for biotech. One …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
